FDA Approach To Third Drug Class Expected Within Months
Executive Summary
FDA will include industry in the process of developing a distribution channel for drugs between the traditional prescription and over-the-counter spaces, agency representatives said at the Consumer Healthcare Products Association's Regulatory and Scientific Conference
You may also be interested in...
Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
FDA's authority to require behind-the-counter sale and other restrictions for some nonprescription switches is strengthened by risk management provisions of "FDA Revitalization" bills pending in Congress, according to former FDA Deputy Commissioner Scott Gottlieb
Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
FDA's authority to require behind-the-counter sale and other restrictions for some nonprescription switches is strengthened by risk management provisions of "FDA Revitalization" bills pending in Congress, according to former FDA Deputy Commissioner Scott Gottlieb
FDA Open To Behind-The-Counter NDAs While Mulling “Continuum” Class
FDA is open to behind-the-counter switch applications in which companies propose innovative methods to solve access or selection issues, according to Office of Nonprescription Products staff